288 related articles for article (PubMed ID: 19754465)
21. Reduced anticonvulsant efficacy of valproic acid in dopamine beta-hydroxylase knockout mice.
Schank JR; Liles LC; Weinshenker D
Epilepsy Res; 2005 Jun; 65(1-2):23-31. PubMed ID: 15955669
[TBL] [Abstract][Full Text] [Related]
22. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium.
Chang P; Orabi B; Deranieh RM; Dham M; Hoeller O; Shimshoni JA; Yagen B; Bialer M; Greenberg ML; Walker MC; Williams RS
Dis Model Mech; 2012 Jan; 5(1):115-24. PubMed ID: 21876211
[TBL] [Abstract][Full Text] [Related]
23. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Hoffmann K; Czapp M; Löscher W
Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
[TBL] [Abstract][Full Text] [Related]
24. Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
Okada A; Kurihara H; Aoki Y; Bialer M; Fujiwara M
Birth Defects Res B Dev Reprod Toxicol; 2004 Feb; 71(1):47-53. PubMed ID: 14991910
[TBL] [Abstract][Full Text] [Related]
25. The involvement of taurine in the action mechanism of sodium valproate (VPA) in the treatment of epilepsy.
Anyanwu E; Harding GF
Acta Physiol Pharmacol Ther Latinoam; 1993; 43(1-2):20-7. PubMed ID: 7865870
[TBL] [Abstract][Full Text] [Related]
26. Valproic Acid: second generation.
Bialer M; Yagen B
Neurotherapeutics; 2007 Jan; 4(1):130-7. PubMed ID: 17199028
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.
Keane PE; Simiand J; Morre M
Methods Find Exp Clin Pharmacol; 1985 Feb; 7(2):83-6. PubMed ID: 2859407
[TBL] [Abstract][Full Text] [Related]
28. Effects of valproic acid on sleep in children with epilepsy.
Schmitt B; Martin F; Critelli H; Molinari L; Jenni OG
Epilepsia; 2009 Aug; 50(8):1860-7. PubMed ID: 19453719
[TBL] [Abstract][Full Text] [Related]
29. Valproic acid- and lithium-sensitivity in prs mutants of Saccharomyces cerevisiae.
Kleineidam A; Vavassori S; Wang K; Schweizer LM; Griac P; Schweizer M
Biochem Soc Trans; 2009 Oct; 37(Pt 5):1115-20. PubMed ID: 19754463
[TBL] [Abstract][Full Text] [Related]
30. Increase of fetal hemoglobin synthesis indicating differentiation induction in children receiving valproic acid.
Kieslich M; Schwabe D; Cinatl J; Driever PH
Pediatr Hematol Oncol; 2003; 20(1):15-22. PubMed ID: 12687749
[TBL] [Abstract][Full Text] [Related]
31. Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation.
D'Souza A; Onem E; Patel P; La Gamma EF; Nankova BB
Brain Res; 2009 Jan; 1247():1-10. PubMed ID: 18976638
[TBL] [Abstract][Full Text] [Related]
32. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited.
Harwood AJ
Mol Psychiatry; 2005 Jan; 10(1):117-26. PubMed ID: 15558078
[TBL] [Abstract][Full Text] [Related]
33. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
Werstuck GH; Kim AJ; Brenstrum T; Ohnmacht SA; Panna E; Capretta A
Bioorg Med Chem Lett; 2004 Nov; 14(22):5465-7. PubMed ID: 15482904
[TBL] [Abstract][Full Text] [Related]
34. Teratogenicity of valproate conjugates with anticonvulsant activity in mice.
Spiegelstein O; Chatterjie N; Alexander G; Finnell RH
Epilepsy Res; 2003 Dec; 57(2-3):145-52. PubMed ID: 15013055
[TBL] [Abstract][Full Text] [Related]
35. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement.
Gotfryd K; Owczarek S; Hoffmann K; Klementiev B; Nau H; Berezin V; Bock E; Walmod PS
Neuropharmacology; 2007 Mar; 52(3):764-78. PubMed ID: 17095022
[TBL] [Abstract][Full Text] [Related]
36. Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.
Pessah N; Bialer M; Wlodarczyk B; Finnell RH; Yagen B
J Med Chem; 2009 Apr; 52(8):2233-42. PubMed ID: 19296679
[TBL] [Abstract][Full Text] [Related]
37. Effect of valproic acid on serotonin-2A receptor signaling in C6 glioma cells.
Sullivan NR; Burke T; Siafaka-Kapadai A; Javors M; Hensler JG
J Neurochem; 2004 Sep; 90(5):1269-75. PubMed ID: 15312182
[TBL] [Abstract][Full Text] [Related]
38. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts.
Gurvich N; Klein PS
Pharmacol Ther; 2002 Oct; 96(1):45-66. PubMed ID: 12441177
[TBL] [Abstract][Full Text] [Related]
39. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?
Li X; Ketter TA; Frye MA
J Affect Disord; 2002 May; 69(1-3):1-14. PubMed ID: 12103447
[TBL] [Abstract][Full Text] [Related]
40. Effects of divalproex sodium on hemoglobin level.
Taher AT; Musallam KM; Nasreddine W; Perrine SP; El-Hajj TI; Beydoun A
Blood Cells Mol Dis; 2009; 43(1):49-52. PubMed ID: 19254854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
